Synergy Pharmaceuticals Inc fka SGYPQ

[iandy]

ARDX - FierceBiotech

The topline results from the T3MPO-1 trial, the first of two phase 3 tests in IBS-C in more than 600 patients, hit its primary endpoint, showing that a greater proportion of tenapanor-treated patients compared to placebo-treated patients (27% vs 18.7%) had at least a 30% reduction in abdominal pain.

It also hit seven of the eight secondary endpoints, missing the target in bowel movement rates, and there were some AE issues with tenapanor as compared with a dummy treatment, seeing higher rates of diarrhea (14.6% vs 1.7%) and slightly more for nausea (2.6% vs 1.7%).

Patients pulling out of the trial due to diarrhea were 5.9% for tenapanor, compared to just 0.6% for the placebo group. More details from the study will be published down the line.

http://www.fiercebiotech.com/biotech/ardelyx-reports-positive-phase-3-data-but-shares-fall-hard-premarket

Let the bidding begin...
In my dreams probably:)